Table 2.
Published SPLIS gonadal clinical phenotype, in all cases, the phenotype was noted post-birth/in early infancy.
Pt no. | SGPL1 pathogenic variant | Ethnicity | Sex | Concomitant adrenal disease (Y/N) | Microphallus (Y/N) | Cryptorchidism (Y/N) | LH/FSH at presentation | HCG testing /LHRH and result | Anti-Müllerian hormone level | Publication |
---|---|---|---|---|---|---|---|---|---|---|
4† | c.261+1G | Peruvian | M | Y | Y | Bilateral | Raised (LH 36 IU/L, FSH 58 IU/L) | U | 40 pmol/L (NR 600–2000, ECLIA) | Prasad (4) |
8† | c.511A>G, p.N171D | Pakistani | M | Y | Y | Bilateral | Raised (LH 27 IU/L, FSH 71 IU/L) | No response in testosterone (1.0 nmol/L day 1, 0.9 nmol/L day 3) to hCG stimulation, ‘flat’ androstenedione and DHT response | U | Maharaj (7) |
22 | c.868T>c, p.F290L; c.993C<G, p.Y331* | White American | M | Y | Y | Bilateral | Raised (LH 23 IU/L, FSH 41 IU/L) | U | U | Taylor (9) |
23 | c.934delC, p. L312Yfs*30 | White European | M | Y | Y | Bilateral | Raised* | U | U | Janecke (2) |
26† | c.1018C >T, p.R340W | Turkish | M | Y | N | Bilateral | Raised (LH 52.6 IU/L, FSH 71.5 IU/L) | U | 11.6 ng/mL (NR 14–466) | Menevse (20) |
31 | c.1233delC, p.F411Lfs*56 | Afghan | M | Y | N | Bilateral | U | U | U | Bamborshke (5) |
34 | c.1513C >T, p.R505* | Arabic | M | Y | Y | Bilateral | Raised* | Lack of testosterone response to hCG stimulation*; exaggerated gonadotrophin response to LHRH | Low* | Janecke (2) |
35 | c.1513C >T, p.R505* | Arabic | M | Y | Y | Bilateral | Raised* | Lack of testosterone response to hCG stimulation*; exaggerated gonadotrophin response to LHRH | Low* | Janecke (2) |
36 | c.1566+2T>C; c.854G>A, C285Y | Unknown | M | Y | Y | U | U | U | U | Zhao (10) |
Patient numbers correspond to numbers allocated for PAI phenotype in Table 1.
*Details of results not published;†Patients referred to the QMUL cohort.
FSH, follicle-stimulating hormone; hCG, human chorionic gonadotropin; LH, luteinizing hormone; LHRH, luteinizing hormone releasing hormone; N, no; U, unknown; Y, yes.